Ignyta - Company & Market Research Reports

Ignyta is an oncology biotechnology company. The company focuses on integrated therapeutic (Rx) and companion diagnostic (Dx) strategies for treating cancer patients. Its Rx is focused on developing molecularly targeted therapies for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify the patients who will benefit from the therapies it develops. The company was founded in 2011 and is headquartered in San Diego, California.


Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022 - Product Thumbnail Image

Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022

  • Report
  • 168 Pages
From
Papillary Thyroid Cancer Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017 - Product Thumbnail Image

Papillary Thyroid Cancer Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

  • Report
  • 72 Pages
From
Rheumatoid - Inflammatory Diseases Markers Tests - Medical Devices Pipeline Assessment, 2017 - Product Thumbnail Image

Rheumatoid - Inflammatory Diseases Markers Tests - Medical Devices Pipeline Assessment, 2017

  • Report
  • 161 Pages
From
Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018 - Product Thumbnail Image

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018

  • Report
  • 2500 Pages
From
TRK1-Transforming Tyrosine Kinase (Trk-A or High Affinity Nerve Growth Factor Receptor) Antagonist -Pipeline Insight, 2018 - Product Thumbnail Image

TRK1-Transforming Tyrosine Kinase (Trk-A or High Affinity Nerve Growth Factor Receptor) Antagonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Thyroid Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Thyroid Cancer - Pipeline Review, H1 2018

  • Report
  • 567 Pages
From
Papillary Thyroid Cancer - Pipeline Review, H2 2016 - Product Thumbnail Image

Papillary Thyroid Cancer - Pipeline Review, H2 2016

  • Report
  • 72 Pages
From
Papillary Thyroid Cancer - Pipeline Insight, 2018 - Product Thumbnail Image

Papillary Thyroid Cancer - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Papillary Thyroid Cancer - Pipeline Review, H1 2016 - Product Thumbnail Image

Papillary Thyroid Cancer - Pipeline Review, H1 2016

  • Report
  • 106 Pages
From
Papillary Thyroid Cancer - Pipeline Review, H2 2015 - Product Thumbnail Image

Papillary Thyroid Cancer - Pipeline Review, H2 2015

  • Report
  • 115 Pages
From
Medullary Thyroid Cancer - Pipeline Review, H1 2015 - Product Thumbnail Image

Medullary Thyroid Cancer - Pipeline Review, H1 2015

  • Report
  • 95 Pages
From
Neuroblastoma - Pipeline Review, H2 2017 - Product Thumbnail Image

Neuroblastoma - Pipeline Review, H2 2017

  • Report
  • 506 Pages
From
Neuroblastoma - Pipeline Review, H1 2017 - Product Thumbnail Image

Neuroblastoma - Pipeline Review, H1 2017

  • Report
  • 417 Pages
From
Cancer Stem Cell Therapies Market, 2017-2030 - Product Thumbnail Image

Cancer Stem Cell Therapies Market, 2017-2030

  • Report
  • 270 Pages
From
Oncology Drug Report - Xalkori - Crizotinib - 2011-2015 Analysis; 2016-2021 Expectations - Product Thumbnail Image

Oncology Drug Report - Xalkori - Crizotinib - 2011-2015 Analysis; 2016-2021 Expectations

  • Report
  • 48 Pages
From
Companion Diagnostics Market: By Technology, ISH, IHC, Others Applications End Users - Forecast 2017-2022 - Product Thumbnail Image

Companion Diagnostics Market: By Technology, ISH, IHC, Others Applications End Users - Forecast 2017-2022

  • Report
  • 86 Pages
From
Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

  • Report
  • 244 Pages
From
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018 - Product Thumbnail Image

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018

  • Report
  • 132 Pages
From
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2017 - Product Thumbnail Image

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2017

  • Report
  • 61 Pages
From
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2017 - Product Thumbnail Image

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2017

  • Report
  • 57 Pages
From
Loading Indicator
adroll